Entrepreneurs Fund

General Fusion Inc. is a Canadian company focused on the development of commercial Magnetized Target Fusion (MTF), a promising hybrid approach that combines elements of magnetic fusion and inertial confinement fusion. Founded in 2002 and based in Burnaby, the company aims to create utility-scale fusion power plants that can provide clean, safe, and abundant energy. General Fusion is pioneering a patent-pending concept that leverages advancements in MTF, which has seen limited exploration since the 1970s. The company is dedicated to demonstrating and commercializing this innovative energy solution by the end of the decade. It is supported by a network of global energy venture capital firms, industry leaders, and technology innovators, all working to reduce technical risks and accelerate the path to viable fusion energy.

Realeyes is a pioneering company specializing in computer vision and emotion AI. It helps businesses enhance customer experiences and drive growth by measuring human responses to video content at scale and speed. Using webcams and advanced machine learning techniques, Realeyes' platform analyzes facial expressions to quantify emotional reactions, enabling clients like Mars Inc., P&G, and Netflix to create targeted, optimized content. Over 200 leading brands and media companies rely on Realeyes for these insights.

OptiNose, Inc., established in 2010 and headquartered in Yardley, Pennsylvania, is a specialty pharmaceutical company specializing in nasal drug delivery technologies and therapies. The company's proprietary Bi-Directional Delivery system enables more efficient drug deposition in the upper posterior regions of the nasal cavity, unlike traditional devices. This technology is employed in OptiNose's lead product, XHANCE, a nasal spray utilizing the Exhalation Delivery System (EDS) to deliver a topically-acting corticosteroid for treating chronic rhinosinusitis with and without nasal polyps. OptiNose also has products in development for chronic sinusitis and rare genetic disorders like Prader-Willi syndrome. The company's technologies offer high dose reproducibility, faster onset of action, greater effect with lower doses, and reduced side effects. OptiNose has offices in Norway and the UK, and its products are commercialized through strategic partnerships.

Vasopharm GmbH is a biopharmaceutical company based in Würzburg, Germany, that focuses on discovering and developing innovative therapeutics for cerebro- and cardiovascular diseases. Established in 1998, the company targets acute niche indications with significant unmet medical needs, emphasizing clinical efficacy in its drug development efforts. Vasopharm's therapeutic pipeline includes VAS203, an allosteric nitric oxide synthase inhibitor designed to reduce excessive nitric oxide production in cerebral vessels, thereby preventing dangerous increases in intracranial pressure after traumatic brain injury. Another key candidate, VAS2870, is a modulator of NAD(P)H oxidase, aimed at treating peripheral arterial occlusive diseases. Through its research, Vasopharm aims to influence the bioavailability of nitric oxide, a critical cellular signaling molecule involved in various physiological and pathological processes.

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

General Fusion Inc. is a Canadian company focused on the development of commercial Magnetized Target Fusion (MTF), a promising hybrid approach that combines elements of magnetic fusion and inertial confinement fusion. Founded in 2002 and based in Burnaby, the company aims to create utility-scale fusion power plants that can provide clean, safe, and abundant energy. General Fusion is pioneering a patent-pending concept that leverages advancements in MTF, which has seen limited exploration since the 1970s. The company is dedicated to demonstrating and commercializing this innovative energy solution by the end of the decade. It is supported by a network of global energy venture capital firms, industry leaders, and technology innovators, all working to reduce technical risks and accelerate the path to viable fusion energy.

D3O is an innovative company specializing in impact protection solutions through the development of patented smart materials. Its technology, based on non-Newtonian fluids, produces shock-absorbing materials utilized across various sectors, including motorcycle, sports, footwear, electronics, military, and workwear. D3O® gained recognition during the 2006 Winter Olympics when it was adopted by the US and Canadian ski teams for its advanced soft armor. The company's products are characterized by their lightweight, flexible, and breathable design, providing effective protection without compromising comfort. D3O continues to lead the market in impact protection and shock absorption, offering pioneering solutions that enhance safety for soldiers, professional athletes, and industrial workers alike.

Exosect Limited, established in 2001 as a spin-out from the University of Southampton, specializes in developing innovative platforms that enhance the delivery of biological and synthetic active ingredients for pesticide manufacturers. The company's proprietary technologies, including the Entostat and Entomag delivery platforms, address challenges such as pest resistance, regulatory compliance, and food safety residues. The Entostat platform utilizes an electrostatically charged micro powder for microencapsulation and controlled release of active ingredients, while the Entomag platform employs ferrous micro powder for targeted delivery, particularly against crawling insects in public health applications. With a robust portfolio of 41 patents and 28 national product registrations, Exosect is strategically positioned to commercialize its patented technologies across agriculture, public health, and animal health sectors, aiming to improve pest control and food protection. The company is headquartered in Winchester, United Kingdom.

Rakuten Fits Me is a provider of innovative fit recommendation solutions tailored for eCommerce fashion retailers, focusing on enhancing the online shopping experience by prioritizing fit and body shapes. The company utilizes a combination of garment data and shopper-specific measurements, derived from factors such as height, weight, age, and body shape, to accurately recommend the best-fitting sizes for customers. By leveraging deep statistical analysis of extensive body scan data, Rakuten Fits Me enables its data scientists to infer precise measurements that align with individual shopper profiles. Each garment is meticulously analyzed by garment technologists, who consider various elements, including silhouette and stretch, to inform fit preferences. This personalized approach helps shoppers make informed decisions, ensuring they select clothing that fits well and meets their style expectations. Ultimately, Rakuten Fits Me stands out as a unique size and fit solution provider, aligning product data with shopper body data to deliver an optimal fit experience consistently.

SmartKem Limited is a Manchester-based company that develops and markets organic semiconductors for various display technologies, including liquid crystal and organic light-emitting diode displays. Established in 2008, the company specializes in the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for use in transistor backplanes. SmartKem's patented TRUFLEX inks enable the production of organic thin-film transistor circuits on low-cost substrates, facilitating applications in mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company generates revenue through the sale of these inks and demonstration products, contributing to the advancement of a new generation of displays and sensors.

OptiNose, Inc., established in 2010 and headquartered in Yardley, Pennsylvania, is a specialty pharmaceutical company specializing in nasal drug delivery technologies and therapies. The company's proprietary Bi-Directional Delivery system enables more efficient drug deposition in the upper posterior regions of the nasal cavity, unlike traditional devices. This technology is employed in OptiNose's lead product, XHANCE, a nasal spray utilizing the Exhalation Delivery System (EDS) to deliver a topically-acting corticosteroid for treating chronic rhinosinusitis with and without nasal polyps. OptiNose also has products in development for chronic sinusitis and rare genetic disorders like Prader-Willi syndrome. The company's technologies offer high dose reproducibility, faster onset of action, greater effect with lower doses, and reduced side effects. OptiNose has offices in Norway and the UK, and its products are commercialized through strategic partnerships.

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Xeros Ltd. is a new company focused on the development of "virtually waterless" laundry cleaning. Harnessing over 30 years of research by Professor Stephen Burkinshaw and the University of Leeds, Xeros is the brand name for a patented polymer based cleaning that creates step change advantage in the cost and environmental impact of aqueous wash cleaning.

Trusted Insight is an online investment network that connects institutional investors with curated information and resources related to alternative assets. Established in 2010 by Alex Bangash, the platform boasts over 140,000 members who manage more than $18 trillion in assets, with approximately 30,000 institutional investors interacting with the network weekly. Trusted Insight offers a range of services, including news updates, job listings, rankings, and both online and offline events, creating a forum for investment professionals to share insights and stay informed about trends in private equity, hedge funds, real estate, and private companies. With offices in New York City and San Francisco, Trusted Insight has become a rapidly growing and trusted source for alternative investment information.

General Fusion Inc. is a Canadian company focused on the development of commercial Magnetized Target Fusion (MTF), a promising hybrid approach that combines elements of magnetic fusion and inertial confinement fusion. Founded in 2002 and based in Burnaby, the company aims to create utility-scale fusion power plants that can provide clean, safe, and abundant energy. General Fusion is pioneering a patent-pending concept that leverages advancements in MTF, which has seen limited exploration since the 1970s. The company is dedicated to demonstrating and commercializing this innovative energy solution by the end of the decade. It is supported by a network of global energy venture capital firms, industry leaders, and technology innovators, all working to reduce technical risks and accelerate the path to viable fusion energy.

Vasopharm GmbH is a biopharmaceutical company based in Würzburg, Germany, that focuses on discovering and developing innovative therapeutics for cerebro- and cardiovascular diseases. Established in 1998, the company targets acute niche indications with significant unmet medical needs, emphasizing clinical efficacy in its drug development efforts. Vasopharm's therapeutic pipeline includes VAS203, an allosteric nitric oxide synthase inhibitor designed to reduce excessive nitric oxide production in cerebral vessels, thereby preventing dangerous increases in intracranial pressure after traumatic brain injury. Another key candidate, VAS2870, is a modulator of NAD(P)H oxidase, aimed at treating peripheral arterial occlusive diseases. Through its research, Vasopharm aims to influence the bioavailability of nitric oxide, a critical cellular signaling molecule involved in various physiological and pathological processes.

NewMotion specializes in providing advanced charging solutions for electric vehicle (EV) drivers, focusing on facilitating the use of renewable energy for charging. The company operates one of the largest and fastest-growing charging networks in Europe, with over 12,000 connected charge points. Two out of three electric vehicle drivers in the Netherlands utilize NewMotion's charging solutions. Additionally, NewMotion offers charging points and solutions for businesses, partnering with leasing companies and car manufacturers to enhance the accessibility of charging infrastructure. The company is actively expanding its network across the Netherlands, Belgium, Germany, and Norway, making electric driving more convenient and enjoyable for users.

Exosect Limited, established in 2001 as a spin-out from the University of Southampton, specializes in developing innovative platforms that enhance the delivery of biological and synthetic active ingredients for pesticide manufacturers. The company's proprietary technologies, including the Entostat and Entomag delivery platforms, address challenges such as pest resistance, regulatory compliance, and food safety residues. The Entostat platform utilizes an electrostatically charged micro powder for microencapsulation and controlled release of active ingredients, while the Entomag platform employs ferrous micro powder for targeted delivery, particularly against crawling insects in public health applications. With a robust portfolio of 41 patents and 28 national product registrations, Exosect is strategically positioned to commercialize its patented technologies across agriculture, public health, and animal health sectors, aiming to improve pest control and food protection. The company is headquartered in Winchester, United Kingdom.

Rakuten Fits Me is a provider of innovative fit recommendation solutions tailored for eCommerce fashion retailers, focusing on enhancing the online shopping experience by prioritizing fit and body shapes. The company utilizes a combination of garment data and shopper-specific measurements, derived from factors such as height, weight, age, and body shape, to accurately recommend the best-fitting sizes for customers. By leveraging deep statistical analysis of extensive body scan data, Rakuten Fits Me enables its data scientists to infer precise measurements that align with individual shopper profiles. Each garment is meticulously analyzed by garment technologists, who consider various elements, including silhouette and stretch, to inform fit preferences. This personalized approach helps shoppers make informed decisions, ensuring they select clothing that fits well and meets their style expectations. Ultimately, Rakuten Fits Me stands out as a unique size and fit solution provider, aligning product data with shopper body data to deliver an optimal fit experience consistently.

Xeros Ltd. is a new company focused on the development of "virtually waterless" laundry cleaning. Harnessing over 30 years of research by Professor Stephen Burkinshaw and the University of Leeds, Xeros is the brand name for a patented polymer based cleaning that creates step change advantage in the cost and environmental impact of aqueous wash cleaning.

Realeyes is a pioneering company specializing in computer vision and emotion AI. It helps businesses enhance customer experiences and drive growth by measuring human responses to video content at scale and speed. Using webcams and advanced machine learning techniques, Realeyes' platform analyzes facial expressions to quantify emotional reactions, enabling clients like Mars Inc., P&G, and Netflix to create targeted, optimized content. Over 200 leading brands and media companies rely on Realeyes for these insights.

Exosect Limited, established in 2001 as a spin-out from the University of Southampton, specializes in developing innovative platforms that enhance the delivery of biological and synthetic active ingredients for pesticide manufacturers. The company's proprietary technologies, including the Entostat and Entomag delivery platforms, address challenges such as pest resistance, regulatory compliance, and food safety residues. The Entostat platform utilizes an electrostatically charged micro powder for microencapsulation and controlled release of active ingredients, while the Entomag platform employs ferrous micro powder for targeted delivery, particularly against crawling insects in public health applications. With a robust portfolio of 41 patents and 28 national product registrations, Exosect is strategically positioned to commercialize its patented technologies across agriculture, public health, and animal health sectors, aiming to improve pest control and food protection. The company is headquartered in Winchester, United Kingdom.

Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled medicines for the treatment of asthma and chronic obstructive pulmonary disease. Established in 2006, the company specializes in creating generic mono and combination therapies that incorporate inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. Prosonix employs proprietary ultrasonic particle engineering technologies to enhance the manufacture of inhaled medications, enabling the design of drug particles tailored for effective inhalation. The company also works on dual and triple combination therapies to provide comprehensive treatment options for respiratory conditions. As of mid-2015, Prosonix operates as a subsidiary of Circassia Limited.

Rakuten Fits Me is a provider of innovative fit recommendation solutions tailored for eCommerce fashion retailers, focusing on enhancing the online shopping experience by prioritizing fit and body shapes. The company utilizes a combination of garment data and shopper-specific measurements, derived from factors such as height, weight, age, and body shape, to accurately recommend the best-fitting sizes for customers. By leveraging deep statistical analysis of extensive body scan data, Rakuten Fits Me enables its data scientists to infer precise measurements that align with individual shopper profiles. Each garment is meticulously analyzed by garment technologists, who consider various elements, including silhouette and stretch, to inform fit preferences. This personalized approach helps shoppers make informed decisions, ensuring they select clothing that fits well and meets their style expectations. Ultimately, Rakuten Fits Me stands out as a unique size and fit solution provider, aligning product data with shopper body data to deliver an optimal fit experience consistently.

NewMotion specializes in providing advanced charging solutions for electric vehicle (EV) drivers, focusing on facilitating the use of renewable energy for charging. The company operates one of the largest and fastest-growing charging networks in Europe, with over 12,000 connected charge points. Two out of three electric vehicle drivers in the Netherlands utilize NewMotion's charging solutions. Additionally, NewMotion offers charging points and solutions for businesses, partnering with leasing companies and car manufacturers to enhance the accessibility of charging infrastructure. The company is actively expanding its network across the Netherlands, Belgium, Germany, and Norway, making electric driving more convenient and enjoyable for users.

SOASTA, Inc. is a performance analytics platform that specializes in cloud testing and monitoring solutions for web and mobile applications. Founded in 2006 and headquartered in Mountain View, California, the company provides comprehensive tools that help digital businesses analyze and optimize their performance in real-time. Its offerings include mPulse, a real user monitoring solution that correlates performance with business outcomes; CloudTest, a platform for load and performance testing; TouchTest, which focuses on mobile functional test automation; and the Digital Operations Center, which delivers insights into performance metrics. SOASTA has conducted over 10 million tests and measured more than 100 billion user experiences, serving a range of industry-leading clients. The company also offers a variety of support services, including testing consultation, training, and development assistance, ensuring that clients can effectively manage their digital performance strategies. As of 2017, SOASTA operates as a subsidiary of Akamai Technologies.

Cytoo SA is a life sciences company based in Grenoble, France, specializing in micropattern-enhanced cell-based assays. Founded in 2008, the company develops, manufactures, and commercializes innovative technologies for cell analysis aimed at the life sciences research community. Cytoo's product offerings include CYTOO chips, which feature glass coverslip formats with micropatterns for research applications, and CYTOOchips Mini, designed as standard glass bottom microplates. Additionally, the company provides CYTOOplates with adhesive micropatterns for immunofluorescence assays and CYTOOchambers for high-resolution timelapse live microscopy. These solutions facilitate a variety of research areas, including cell shape analysis, cytoskeletal dynamics, and quantitative cell phenotyping. Cytoo also offers assay development services, focusing on enhancing the reliability and robustness of cellular analysis while addressing the specific needs of researchers.

Exosect Limited, established in 2001 as a spin-out from the University of Southampton, specializes in developing innovative platforms that enhance the delivery of biological and synthetic active ingredients for pesticide manufacturers. The company's proprietary technologies, including the Entostat and Entomag delivery platforms, address challenges such as pest resistance, regulatory compliance, and food safety residues. The Entostat platform utilizes an electrostatically charged micro powder for microencapsulation and controlled release of active ingredients, while the Entomag platform employs ferrous micro powder for targeted delivery, particularly against crawling insects in public health applications. With a robust portfolio of 41 patents and 28 national product registrations, Exosect is strategically positioned to commercialize its patented technologies across agriculture, public health, and animal health sectors, aiming to improve pest control and food protection. The company is headquartered in Winchester, United Kingdom.

Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled medicines for the treatment of asthma and chronic obstructive pulmonary disease. Established in 2006, the company specializes in creating generic mono and combination therapies that incorporate inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. Prosonix employs proprietary ultrasonic particle engineering technologies to enhance the manufacture of inhaled medications, enabling the design of drug particles tailored for effective inhalation. The company also works on dual and triple combination therapies to provide comprehensive treatment options for respiratory conditions. As of mid-2015, Prosonix operates as a subsidiary of Circassia Limited.

General Fusion Inc. is a Canadian company focused on the development of commercial Magnetized Target Fusion (MTF), a promising hybrid approach that combines elements of magnetic fusion and inertial confinement fusion. Founded in 2002 and based in Burnaby, the company aims to create utility-scale fusion power plants that can provide clean, safe, and abundant energy. General Fusion is pioneering a patent-pending concept that leverages advancements in MTF, which has seen limited exploration since the 1970s. The company is dedicated to demonstrating and commercializing this innovative energy solution by the end of the decade. It is supported by a network of global energy venture capital firms, industry leaders, and technology innovators, all working to reduce technical risks and accelerate the path to viable fusion energy.

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Accept helps companies increase the speed and certainty of new product success and turn product innovation into a competitive advantage. Accept SaaS innovation management solutions help companies engage communities, prioritize and manage new ideas, align products with company strategy, and unify execution across teams.

Xeros Ltd. is a new company focused on the development of "virtually waterless" laundry cleaning. Harnessing over 30 years of research by Professor Stephen Burkinshaw and the University of Leeds, Xeros is the brand name for a patented polymer based cleaning that creates step change advantage in the cost and environmental impact of aqueous wash cleaning.

Exosect Limited, established in 2001 as a spin-out from the University of Southampton, specializes in developing innovative platforms that enhance the delivery of biological and synthetic active ingredients for pesticide manufacturers. The company's proprietary technologies, including the Entostat and Entomag delivery platforms, address challenges such as pest resistance, regulatory compliance, and food safety residues. The Entostat platform utilizes an electrostatically charged micro powder for microencapsulation and controlled release of active ingredients, while the Entomag platform employs ferrous micro powder for targeted delivery, particularly against crawling insects in public health applications. With a robust portfolio of 41 patents and 28 national product registrations, Exosect is strategically positioned to commercialize its patented technologies across agriculture, public health, and animal health sectors, aiming to improve pest control and food protection. The company is headquartered in Winchester, United Kingdom.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

General Fusion Inc. is a Canadian company focused on the development of commercial Magnetized Target Fusion (MTF), a promising hybrid approach that combines elements of magnetic fusion and inertial confinement fusion. Founded in 2002 and based in Burnaby, the company aims to create utility-scale fusion power plants that can provide clean, safe, and abundant energy. General Fusion is pioneering a patent-pending concept that leverages advancements in MTF, which has seen limited exploration since the 1970s. The company is dedicated to demonstrating and commercializing this innovative energy solution by the end of the decade. It is supported by a network of global energy venture capital firms, industry leaders, and technology innovators, all working to reduce technical risks and accelerate the path to viable fusion energy.

Inge Watertechnologies specializes in the development of ultrafiltration technology for water treatment applications. The company's innovative membrane separation process utilizes ultra-small pore filters that effectively remove particles, suspended solids, and microorganisms, including bacteria and viruses. This technology is designed to ensure smart, safe, and reliable solutions for treating various types of water, including drinking water, processed water, seawater, and wastewater. By providing dependable access to clean water, Inge Watertechnologies addresses critical needs in water management and environmental sustainability.

Exosect Limited, established in 2001 as a spin-out from the University of Southampton, specializes in developing innovative platforms that enhance the delivery of biological and synthetic active ingredients for pesticide manufacturers. The company's proprietary technologies, including the Entostat and Entomag delivery platforms, address challenges such as pest resistance, regulatory compliance, and food safety residues. The Entostat platform utilizes an electrostatically charged micro powder for microencapsulation and controlled release of active ingredients, while the Entomag platform employs ferrous micro powder for targeted delivery, particularly against crawling insects in public health applications. With a robust portfolio of 41 patents and 28 national product registrations, Exosect is strategically positioned to commercialize its patented technologies across agriculture, public health, and animal health sectors, aiming to improve pest control and food protection. The company is headquartered in Winchester, United Kingdom.

VAIREX International Limited specializes in designing, manufacturing, and supplying air management systems primarily for the hydrogen fuel cell and diesel emissions control markets. The company provides efficient air systems that include restrained vane compressors and regenerative blowers, which are equipped with integrated motors and controllers. Its clientele consists of original equipment manufacturers and Tier One suppliers in the fuel cell and diesel sectors, serving various applications such as industrial electric vehicles, power generation, and automotive markets across Europe, Asia, and North America. Established in 2007, VAIREX is headquartered in Cambridge, United Kingdom, with additional offices in Boulder, Colorado, and Tokyo, Japan.

Exosect Limited, established in 2001 as a spin-out from the University of Southampton, specializes in developing innovative platforms that enhance the delivery of biological and synthetic active ingredients for pesticide manufacturers. The company's proprietary technologies, including the Entostat and Entomag delivery platforms, address challenges such as pest resistance, regulatory compliance, and food safety residues. The Entostat platform utilizes an electrostatically charged micro powder for microencapsulation and controlled release of active ingredients, while the Entomag platform employs ferrous micro powder for targeted delivery, particularly against crawling insects in public health applications. With a robust portfolio of 41 patents and 28 national product registrations, Exosect is strategically positioned to commercialize its patented technologies across agriculture, public health, and animal health sectors, aiming to improve pest control and food protection. The company is headquartered in Winchester, United Kingdom.

iPolicy Networks is the developer of the world's first Intrusion Prevention Firewall delivering real-time, consistent security enforcement for enterprises, carriers and managed security service providers. The iPolicy Intrusion Prevention Firewall supports multiple security functions built on iPolicy's Single Pass Architecture(TM) that enables superior performance even under heavy traffic load.

t2cure GmbH is a biopharmaceutical company based in Frankfurt am Main, Germany, focused on developing progenitor cell-based regenerative therapeutics for cardiovascular diseases. Founded in 2006, the company specializes in providing autologous bone marrow-derived progenitor cells as treatments for conditions such as ischemic heart diseases, non-ischemic heart failure, peripheral arterial occlusive disease, and diabetic polyneuropathy. t2cure's innovative therapeutics aim to enhance recovery by improving blood flow and promoting tissue repair through the release of regenerative messenger substances. By harnessing the potential of mononuclear cells obtained from patients' bone marrow, t2cure seeks to offer new treatment options for individuals suffering from various cardiovascular ailments.

iPolicy Networks is the developer of the world's first Intrusion Prevention Firewall delivering real-time, consistent security enforcement for enterprises, carriers and managed security service providers. The iPolicy Intrusion Prevention Firewall supports multiple security functions built on iPolicy's Single Pass Architecture(TM) that enables superior performance even under heavy traffic load.

MBlox, established in 1999, is a pioneering global mobile messaging company. It maintains over 100 direct carrier relationships and is renowned for its expertise in SMS services. The company's cloud-based platform processes 7 billion mobile messages annually for more than 4,000 clients, ranging from start-ups to multinational corporations. MBlox offers 24/7 email support and customizable support packages to cater to diverse business needs. Its services span various sectors, including financial services, government, transportation, retail, and advertising.